Next Article in Journal
Targeting Antigens for Universal Influenza Vaccine Development
Next Article in Special Issue
The Pro-Inflammatory Chemokines CXCL9, CXCL10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-Dependent Manner
Previous Article in Journal
Phylogenetic Networks and Parameters Inferred from HIV Nucleotide Sequences of High-Risk and General Population Groups in Uganda: Implications for Epidemic Control
Previous Article in Special Issue
Profiles of Peripheral Immune Cells of Uncomplicated COVID-19 Cases with Distinct Viral RNA Shedding Periods
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 13
Issue 6
10.3390/v13060972
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Identification of Novel Candidate CD8+ T Cell Epitopes of the SARS-CoV2 with Homology to Other Seasonal Coronaviruses

by
Pradeep Darshana Pushpakumara
1,
Deshan Madhusanka
1,
Saubhagya Dhanasekara
1,
Chandima Jeewandara
1,
Graham S. Ogg
2 and
Gathsaurie Neelika Malavige
1,2,*
1
Centre for Dengue Research, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda 10250, Sri Lanka
2
MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX1 4BH, UK
*
Author to whom correspondence should be addressed.
Viruses 2021, 13(6), 972; https://doi.org/10.3390/v13060972
Submission received: 29 March 2021 / Revised: 15 May 2021 / Accepted: 21 May 2021 / Published: 24 May 2021
(This article belongs to the Special Issue SARS-CoV-2 Host Cell Interactions)
Review Reports Versions Notes

Abstract

:
Cross-reactive T cell immunity to seasonal coronaviruses (HCoVs) may lead to immunopathology or protection during SARS-CoV2 infection. To understand the influence of cross-reactive T cell responses, we used IEDB (Immune epitope database) and NetMHCpan (ver. 4.1) to identify candidate CD8+ T cell epitopes, restricted through HLA-A and B alleles. Conservation analysis was carried out for these epitopes with HCoVs, OC43, HKU1, and NL63. 12/18 the candidate CD8+ T cell epitopes (binding score of ≥0.90), which had a high degree of homology (>75%) with the other three HCoVs were within the NSP12 and NSP13 proteins. They were predicted to be restricted through HLA-A*2402, HLA-A*201, HLA-A*206, and HLA-B alleles B*3501. Thirty-one candidate CD8+ T cell epitopes that were specific to SARS-CoV2 virus (<25% homology with other HCoVs) were predominantly identified within the structural proteins (spike, envelop, membrane, and nucleocapsid) and the NSP1, NSP2, and NSP3. They were predominantly restricted through HLA-B*3501 (6/31), HLA-B*4001 (6/31), HLA-B*4403 (7/31), and HLA-A*2402 (8/31). It would be crucial to understand T cell responses that associate with protection, and the differences in the functionality and phenotype of epitope specific T cell responses, presented through different HLA alleles common in different geographical groups, to understand disease pathogenesis.

1. Introduction

Infection due to the SARS-CoV2 virus is currently the leading cause of mortality among elderly and vulnerable groups in many countries. Outbreaks of COVID-19 are now reported in 220 countries in the world [1], with some countries experiencing a massive second wave. The majority of those who are infected with SARS-CoV2 experience asymptomatic or mild illness, whereas severe illness and fatalities are seen in older individuals and in those with comorbidities such as diabetes, cancer, and cardiovascular disease [2,3,4]. However, the observed case fatality ratios (CFRs) vary widely between countries. For instance, countries such as Mexico, Italy, and Iran report CFRs of over 3.5%, while countries such as India, Turkey, South Korea report CFRs of <2% [5,6]. The deaths per 100,000 population also varies widely among countries, with many European countries and the US reporting rates of over 100 deaths/100,000 population, while the majority of South Asian and South East Asian countries report death rates <25 deaths/100,000 population, despite the ongoing large outbreaks in the South East Asian region [5].
There have been many factors that have been shown to influence the CFRs in different countries including the proportion of the population aged >70 years of age, the GDP per capita, BCG vaccination status [7,8], climate, population density, and social distancing measures, which could account for the differences in the CFRs. However, there could be many immune factors that also lead to these differences, including immunity to human seasonal coronaviruses (HCoVs), providing cross protection against SARS-CoV2. Children are more frequently exposed to HCoVs compared to adults and recently it was shown that a large proportion of children, who were sampled between the years of 2011 to 2018, between the ages of 1 to 16, had IgG antibodies that cross-react with the spike protein of SARS-CoV-2 [9]. Sera from SARS-CoV2 uninfected individuals who had such cross-reactive antibodies were able to neutralize the pseudotypes of SARS-CoV-2 without causing antibody dependent enhancement of infection [9].
Higher lymphocyte counts and specifically CD8+ T cell counts have been associated with early viral clearance and reduced disease severity [10]. Robust SARS-CoV2 specific CD4+ and CD8+ T cell responses have been detected following natural infection [11,12]. SARS-CoV2 cross reactive T cells have been detected following SARS-CoV1 infection in 2003, which were predominantly directed against the N and structural proteins (NSP7 and NSP13) [13]. Interestingly, SARS-CoV2 cross reactive CD4+ T cells have also been detected in a large proportion of unexposed individuals in some studies, which are thought to be due the presence of T cells specific to HCoVs [12,14]. However, differences in T cell methodology have resulted in differential findings of cross-reactivity related to altered sensitivity and specificity. Ultimately, it will be important to know if T cells can respond to virally infected target cells where naturally processed epitopes are presented. Nevertheless, the presence of such cross-reactive T cell responses has been speculated to protect against infection with the SARS-CoV2 virus and have also speculated to cause disease pathogenesis or response to vaccines [13,14].
As there is a difference in the CFRs among different countries, which are due to multiple factors, it would be important to understand if prior immunity to HCoVs could influence disease outcome when infected with the SARS-CoV2 virus. The predominant CD8+ and CD4+ T cell epitopes recognized by a population are also influenced by the frequency of different HLA types of a population. Therefore, in this study, we analyzed the cross reactivity of all the proteins of the SARS-CoV2 virus with three HCoVs (OC43, NL63, and HKU1) and those that are specific to the SARS-CoV2 virus and then used immune epitope database (IEDB) to predict the CD8+ T cell epitopes predicted to be restricted through the common HLA-Class I alleles in the Sri Lankan population.

2. Materials and Methods

2.1. Data Collection for Seasonal Human Corona Virus (HCoV) Sequence Analysis

The full-length protein sequences of the SARS-CoV2 (NC_045512), OC43 (NC_006213), HKU1 (NC_006577), and NL63 (NC_005831) were obtained from the National Center for Biotechnology Information (NCBI) GenBank (https://www.ncbi.nlm.nih.gov/, 5 October 2020). Four structural and 16 non-structural proteins (NSPs) were individually used for T cell epitope prediction and conservation analysis.

2.2. T-Cell Epitope Prediction for MHC Class I HLA Alleles

IEDB (Immune epitope database) (www.iedb.org, 10 October 2020) [15] along with NetMHCpan (ver. 4.1) [16] was used for finding putative peptide sequences that were restricted through the MHC Class-I HLA alleles, as these methods use algorithms (generated by artificial neural networks), which have accuracy of epitope prediction. HLA-A*02, HLA-A*24, HLA-A*33, HLA-B*35, HLA-B*40, HLA-B*44, HLA-C*07, HLA-C*06, HLA-C*04, and HLA-C*03 alleles were used for this epitope prediction, as these five alleles are the predominant alleles (each allele seen in >10% in the population) in the Sri Lankan population [17]. The epitope predictions were carried out for 8mer, 9mer, and 10mer epitopes. According to the epitope prediction NetMHCpan EL 4, which gives a score ranging from 0.0 to 1.0. Epitopes with a higher score are considered as stronger binders.

2.3. Conservation Analysis of SARS-CoV-2 Proteins and Predicted Epitopes with OC43, HKU1, and NL63

The epitopes which had a predicted binding score of >0.8 through the above approach and were highly conserved between the SARS-CoV2 and OC43, HKU1, and NL63, were further analyzed to determine percentage of identities and similarities between SARS-CoV2 and other HCoVs. The sequences were aligned using the Clustal W on MEGA X software (www.megasoftware.net, 5 October 2020). Conservation of protein sequences were analyzed by using conservation analysis tool available at European Bioinformatics Institute (EBI) (www.ebi.sc.uk, 12 October 2020), IEDB, and Jalview (www.jalview.org, 15 October 2020).

3. Results

In order to identify the possible cross-reactive regions between SARS-CoV2 and other HCoVs, we carried out conservation analysis of SARS-CoV-2 virus with OC43, HKU1, and NL63, which have been seen in Sri Lanka. We analyzed the homology and conservation of the 4 structural and the 16 NSPs of SARS-CoV2 with the 3 other HCoVs (Table S1). The NSP12, NSP13, and NSP16 of the SARS-CoV2 showed ≥65% homology with OC43 and HKU, which are beta coronaviruses, and a >55% homology with NL63, which is an alpha coronavirus.
In contrast, the NSP1 and NSP2 proteins of the SARS-CoV2 showed <20% homology with other three viruses, suggesting that these proteins were more specific for SARS-CoV-2 compared to the other proteins. All four structural proteins (S, E, M, and N), NSP3, and NSP6 showed <35% homology with OC43, HKU1, and NL63. Therefore, immune responses directed at these proteins may also be specific to the SARS-CoV2, unlike immune responses generated against NSP12, NSP13 and NSP16. The SARS-CoV-2 proteins S, E, M, N, and the non-structural proteins showed less homology with NL63 than OC43, and HKU1, suggesting that the. SARS-CoV-2 virus is genetically closer to OC43 and HKU1 than NL63.

3.1. Identification of Possible CD8+ Epitopes of the SARS-CoV2 Virus Restricted through HLA-A Alleles of the SARS-CoV2

The NetMHCpan EL4 epitope prediction tool gives peptide binding scores ranging from 0 to 1.0 and we considered a predicted score ≥0.90 for a peptide as indicative of a stronger binder. None of the 8mer peptides gave a predictive score of ≥0.90. However, 39 9mer peptides gave a high binding score of ≥0.90, which were restricted through different HLA-A alleles, (Table 1). Five of these epitopes were identified from the spike and NSP3 proteins and 4 epitopes each were identified from NSP4, NSP6, NSP12, NSP14, and NSP15. Peptides with high binding scores were not identified from the envelope, NSP1, NSP9, NSP10, NSP11, and NSP16 proteins. The epitopes from NSP3 726YYTSNPTTF734 (predicted to be restricted through HLA-A*2402) and NSP6 70FLLPSLATV78 (predicted to be restricted through HLA-A*0201) gave a score of 0.99, while 1349NYMPYFFTL1357 from NSP3, 420FLLNKEMYL428 from NSP4, and 152ALWEIQQVV160 from NSP8 also gave a score of 0.98 scores. However, they had <45% homology with the other three viruses. 23/39 of the 9mer epitopes predicted in this study were restricted through HLA-A*02 while 16/39 9mer peptides were predicted to be restricted through HLA-A*24. Although HLA-A*33 was an allele seen in over 10% of the Sri Lankan population, 9mers that had a score of ≥0.90 were not identified.
Only four 10mer peptides were predicted to have a score of ≥0.90, two were from spike, and one each from NSP3 and NSP6 proteins (Table 1).

3.2. Identification of Possible CD8+ Epitopes of the SARS-CoV2 Virus Restricted through HLA-B Alleles of the SARS-CoV2

As for HLA-A alleles, we considered a predicted score ≥0.90 for a peptide as indicative of a stronger binder. None of the 8mer peptides were found to give a score of ≥0.90 and therefore, were not predicted to be restricted through HLA-B alleles. However, 38 9mer peptides were identified, which had high binding scores and were predicted to be restricted through HLA-B alleles (Table 2). The highest number of epitopes were predicted from spike protein (5/38) and NSP13 (4/38). Three epitopes were predicted from each of the following proteins: namely the nucleocapsid, NSP2, NSP3, NSP4, and NSP12. No epitopes were identified from envelope, membrane, and NSP11 proteins. Nine epitopes gave a score of 0.99 and were 895IPFAMQMAY903 from spike, 325TPSGTWLTY333 from nucleocapsid, 195SEVGPEHSL203 and 562GETLPTEVL570 both from NSP2, 120EEFEPSTQY128 and 546QEILGTVSW554 both from NSP3, 72LPSLATVAY80 from NSP6, 4SEFSSLPSY12 from NSP8, and 608VENPHLMGW616 from NSP12.
17/38 of these epitopes were predicted to be restricted through HLA-B*35 11/38 through HLA-B*40 and 10/38 through HLA-B*44. While most of these peptides showed <45% homology with OC43, NL63 and HKU-1, 141TEETFKLSY149 and 608VENPHLMGW616 restricted through HLA-B*44, 337VPFVVSTGY345 restricted through HLA-B*35 and 161RELHLSWEV169 restricted through HLA-B*40 showed a homology of >75% with OC43 and HKU-1, which are two other beta coronaviruses.
Only 18 10mers peptides were predicted to have a score of ≥0.90 that were restricted through HLA-B (Table 2), 4/18 were identified NSP3. 10mer peptides with high binding scores were not predicted from envelope, nucleocapsid, NSP1, NSP4, NSP5, NSP6, NSP9, NSP11, and NSP16 9 proteins. 3/18 of these predicted 10mers were shown to be restricted through HLA-B*35, 4/18 through HLA-B*40, and 11/18 through HLA-B*44. Therefore, there may be a higher probability for 10mers to bind to HLA-B*44 alleles.

3.3. Identification of Possible CD8+ Epitopes of the SARS-CoV2 Virus Restricted through HLA-C Alleles of the SARS-CoV2

None of the 8mer and 10mer peptides were found to give a score of ≥0.90 and therefore, were not predicted to be restricted through HLA-C alleles. However, 21 9mer peptides that were identified had high binding scores and were predicted to be restricted through HLA-C alleles (Table 3). The highest number of epitopes were predicted from NSP3 protein (6/21) and spike (4/21). Epitopes were not predicted from each of the following proteins: namely the nucleocapsid, envelop, NSP2, NSP4, NSP6, NSP9, NSP11, NSP12, NSP15 and NSP16.

3.4. Identification of CD8+ T Cell Epitopes of SARS-CoV2, Which Show ≥75% Homology with OC43, HKU1, and NL63

After identification of peptides that had high predicted values to be restricted through the common HLA-A, B, and C alleles present in the Sri Lankan population, we proceeded to identify the regions of the SARS-CoV2 virus, which had a >75% homology with the HCoVs. We then proceeded to identify CD8+ T cell epitopes within these regions, which were candidates to be restricted through these HLA alleles. This was to determine if we could identify CD8+ T cell epitopes of the SARS-CoV2, which were likely to cross-react with the other HCoVs. None of the predicted CD8+ 8mer epitopes identified within the SARS-CoV2 virus gave a high binding score and therefore, only predicted 9mer and 10mer CD8+ T cell epitopes of the SARS-CoV2 virus were analyzed for the degree of homology with OC43, HKU1, and NL63.
Epitopes that were identified to have a ≥75% homology with more than two HCoV viruses are shown in Table 4. Thirty-four 9mer epitopes and 18 10mer peptides identified within the SARS-CoV2 virus had ≥75% homology with ≥2 HCoV viruses. Of the 9mer peptides, 22/34 epitopes gave a peptide binding score of ≥0.90. 11/34 of these CD8+ T cell epitopes within these cross-reactive regions were predicted to be restricted through HLA-A, 6/34 were predicted to be restricted through HLA-B alleles and 5/34 were predicted to be restricted through HLA-C alleles. Six highly cross-reactive CD8+ T cell epitopes (9mers) with high HLA-A (A*201 and A*206) binding scores were identified from the NSP12 and NSP13 (334FVDGVPFVV342). Two of these peptides showed 100% homology with OC43 and HKU1. The Envelope, nucleocapsid proteins and the other non-structural proteins (apart from NSP12 and NSP13) did not have regions with >75% homology with the other HCoVs. The alignment of SARS-CoV2 NSP12 and NSP13, in which most of the cross-reactive epitopes were identified from and their position are shown in Figures S1 and S2.
Of the 10mer peptides analyzed, 18 were identified within SARS-CoV2 to have ≥75% homology with ≥2 HCoVs (Table 4). Only one 10mer peptide identified within NSP-13 (446AEIVDTVSAL455) gave a score of ≥0.90 score. 14/18 of these 10mer CD8+ T cell epitopes were predicted to be restricted through HLA-A and 3/18 were predicted to be restricted through HLA-B alleles. Only one epitope out of 18 was predicted to be restricted through HLA-C. As with the 9mer peptides, 6 of the 10mer peptides, which were highly homologous with OC43, HKU1 and NL63 were found within the NSP12 and NSP13 region.

3.5. Identification of CD8+ T cell Epitopes of SARS-CoV2, Which Show ≤25% Homology with OC43, HKU1, and NL63

After identification of highly cross reactive CD8+ T cell epitopes within the SARS-CoV2, we proceeded to identify regions, which were specific to the virus and did not cross react with other HCoV2, and therefore, are likely to be SARS-CoV2 specific CD8+ T cell epitopes. 9mer peptides of the representing different regions of the SARS-CoV2 virus, which have ≤25% homology with >2 HCoV viruses were analyzed and 60 such potential CD8+ T cell epitopes were identified. (Table 5). 19/60 CD8+ T cell epitopes were predicted to be restricted through HLA-A alleles, 20/60 epitopes were predicted to be restricted through HLA-B alleles and 21/62 epitopes were predicted to be restricted through HLA-C alleles. 31/60 9mer peptides gave a binding score of ≥0.90. 12/31 of these CD8+ T cell epitopes were predicted to be restricted through HLA-A alleles, 14/31 predicted to be restricted through HLA- B alleles and 5/31 predicted to be restricted through HLA- C alleles. A region within the spike protein (686VASQSIIAY694) had no homology with the other HCoVs but had a high binding score of >0.95 to HLA-B*3501 and two other 9mer peptides within the nucleocapsid (325TPSGTWLTY333 and 322MEVTPSGTW330) had <22% homology and were predicted to be restricted through HLA-B*3501 and HLA-B*4403. Three other CD8+ T cell epitopes within NSP2, NSP3 and NSP6, which had high binding scores but had 0% homology were also identified.
We identified 49 10mers as CD8+ T cell epitopes, which had ≤25% homology with two HCoV viruses (Table 5). 5/44 epitopes gave a score of ≥0.90. 22/49 of these CD8+ T cell epitopes were predicted to be restricted through HLA-A, 22/49 were predicated to be restricted through HLA-B alleles and 5/49 were predicated to be restricted through HLA-C alleles. Again, the peptides that had the highest binding scores and least percentage identified were predicted to be restricted through HLA-B*3501 and HLA-B*4403. The highest binders, which were specific to SARS-CoV2, were identified within the spike protein (95TEKSNIIRGW104), NSP2 (489KEIKESVQTF498), and NSP3 (120EEEFEPSTQY129 and 502VPTDNYITTY511).

3.6. Conservational Analysis of the Candidate CD8+ T Cell Epitopes with Binding Scores of ≥0.90

We proceeded to investigate if the 18 candidate CD8+ T cell epitopes that had a percentage identity of >75% with other HCoVs and the 31 SARS-CoV2 specific (<25% percentage identity) were conserved within the SARS-CoV2. We found that these candidate epitopes were highly conserved (Tables S2 and S3) and these regions were highly conserved within the new SARS-CoV2 variants as well (Figures S3 and S4).

3.7. Similarity of Candidate Peptides with Published CD8+ T Cell SARS-CoV2 Epitopes

Several CD8+ T cell epitopes that are restricted through different HLA-A and B alleles have been published [11,18,19,20,21]. We proceeded to find out if any of the candidate CD8+ T cell epitopes were already identified in patients who were naturally infected with the SARS-CoV2 virus. We found that 20/31 candidate highly conserved T cell epitopes which were found to be specific to the SARS-CoV2 (<25% homology with other HCoVs) had been identified in infected individuals (Table S4). In our HLA allele prediction analysis using the dominant HLA alleles in Sri Lanka, although some of the epitopes were predicted to be restricted though HLA-B*3501 and HLA-B*4403, some of these epitopes were found to be restricted through HLA-A*0201, A*1101 and HLA-A*0301.
7/18 of the candidate T cell epitopes, which were found to be cross reactive (>75% homology with the other HCoV2s) were also identified from those who were naturally infected. For the candidate CD8+ T cell epitopes that were found to be cross reactive with other HCoV2, the predicted HLA allele by us and the HLA allele restriction identified following natural infection were similar in 4/7 epitopes (Table S5).

4. Discussion

In this study we have identified candidate CD8+ T cell epitopes, which were highly conserved within SARS-CoV2, and some which show >75% percentage homology with the HCoV2s OC43, HKU1 and NL63, and therefore, are candidates to give rise to cross-reactive T cell responses. The majority of the predicted CD8+ T cell epitopes (binding score of ≥0.90), which had a high degree of homology with the other three HCoV2s were within the NSP12 and NSP13 proteins. They were predicted to be restricted through HLA-A*2402, HLA-A*0201, HLA-A*0206 and HLA-B alleles B*3501. Therefore, the presence of SARS-CoV2 cross reactive CD8+ T cell responses could depend on the frequency of the above HLA-A alleles in a population, as the most cross-reactive candidate CD8+ T cell epitopes are restricted through these alleles.
The frequency of HLA-A*0201 and HLA-A*0206 in the Sri Lankan population are 4.9% to 6.6% and 2.1% to 2.4% respectively, while the frequency of HLA-A*2402 is 20.8% to 30.3% [17,22]. HLA-B*35 frequency in the Sri Lankan population is 21% to 23% [17,22]. In contrast, the most frequent HLA-A alleles in the European, US and Brazilian populations are HLA-A*0201 and A*0206 (24.5% to 27.5%), which are several fold higher than in the Sri Lankan population, while HLA-A*2402 and B*3501 are lower (7.9% to 9.5%) [23,24,25]. In silico analysis recently showed that HLA-A*0201 was associated with a higher risk of COVID-19, while HLA-A*2402 was shown to associate with higher capacity to present SARS-CoV2 antigens [26]. SARS-CoV2 specific HLA-A*0201 CD8+ T cell epitopes were shown to have suboptimal antiviral response and of a reduced frequency when compared to other viral infections such as influenza and Epstein-Barr viral infection [27]. The in-silico analysis showed that countries (Italy, France, Germany, Brazil) in which the most frequent HLA-A allele was A*0201 had the highest COVID-19 case fatality rates (CFRs), whereas those where HLA-A*2402 allele was the most frequent (India, Iran) had lower CFRs [26]. Therefore, it would be important to investigate if certain HLA alleles, presented CD8+ T cell epitopes that associate with protection, whereas if certain other alleles present epitopes that are associated with immunopathology and poor antiviral capacity.
In contrast, the candidate CD8+ T cell epitopes, which were highly conserved identified within SARS-CoV2 virus that are likely to be specific, were predominantly identified within the structural proteins (spike, envelope, membrane, and nucleocapsid) and the NSP1, NSP2, and NSP3. 6/31 of these candidate CD8+ T cell epitopes (binding score of ≥0.90), that were specific to SARS-CoV2 (<25% homology with the HCoVs) were predicted to be restricted through HLA-B*3501, 6/31 through HLA-B*4001, 7/31 through HLA-B*4403 and 8/31 through HLA-A*2402. Only 3/31of the SARS-CoV2 specific candidate T cell epitopes were predicted to be restricted through HLA-A*0201 or A*0206 alleles, common in Europe, USA, and Brazil. Therefore, HLA-A*2402 and HLA-B*3501, HLA-B*4001, and HLA-B*4403, which are predominant HLA alleles in Sri Lanka and India, may present both highly cross-reactive and SARS-CoV2 specific CD8+ T cell epitopes. Indeed, our analysis showed that 20/31 highly conserved, SARS-CoV2 specific candidate CD8+ T cell epitopes were already identified in those with natural infection. Although our HLA allele prediction using the dominant HLA alleles in Sri Lanka predicted these epitopes to be restricted through HLA-B*3501 and HLA-B*4403, some were found to be presented through different HLA alleles in those who were naturally infected in Europe and USA [11,18,21]. However, given that these epitopes are highly conserved within the virus, it is possible that they could be presented by multiple HLA alleles, which should be further investigated.
T cell responses of higher magnitude and breath have been observed in patients who had more severe COVID-19 [12,28]. However, it is not yet known if a higher magnitude and breath of T cell responses in COVID-19 is associated with protection or immunopathology. There is a debate if cross-reactive T cells cause immunopathology in certain viral infections such as in dengue [29,30] and if such cross-reactive T cells in SARS-CoV2 are protective should be investigated. It is hoped that the candidate epitopes presented here, will be of help in subsequent functional T cell analyses, particularly as viral variants emerge as they were found to be highly conserved within the new UK SARS-CoV2 variant, B.1.1.7 and the new South African variant B.1.351. By focusing on highly conserved regions within and between each coronavirus, the candidate epitopes may be of value in understanding immune responses across populations and for future vaccine design. In addition, since many vaccines for COVID-19 are currently been rolled out, it would be crucial to understand T cell responses that associate with protection and the differences in the functionality of epitope specific T cell responses, presented through different HLA alleles.

5. Conclusions

In summary, we have identified candidate SARS-CoV2 CD8+ T cell responses that are highly cross reactive with other HCoVs and that also are specific to SARS-CoV2. Cross-reactive epitopes were predominantly identified from NSP12 and NSP13, while specific epitopes were identified within the structural proteins and NSP1–3. It would be crucial to understand the CD8+ T cell epitopes presented through the most frequent HLA alleles, their phenotype and functionality to better understand the immune responses to SARS-CoV2 and possible implications for vaccines.

Supplementary Materials

https://www.mdpi.com/article/10.3390/v13060972/s1. Figure S1: Multiple alignment of 9mer and 10mer peptide sequences identified from SARS-CoV2 NSP12 with OC43, HKU1, and NL63. All peptides shown have a predicted binding score of ≥0.90, Figure S2: Multiple alignment of 9mer and 10mer peptide sequences identified from SARS-CoV2 NSP13 with OC43, HKU1 and NL63. All peptides shown have a predicted binding score of ≥0.90, Figure S3: Conservational analysis of six candidate CD8+ T cell epitopes that had a high degree of homology (>75%) with HCoVs and a binding score of ≥0.90 with the SARS-CoV2 variants in different countries, and with the new UK variant (B.1.1.7) and the new South African variant B.1.351, Figure S4: Conservational analysis of six candidate CD8+ T cell epitopes that were specific to SARS-CoV2 (<25% homology with HCoVs) and a binding score of ≥0.90 with the SARS-CoV2 variants in different countries, and with the new UK variant (B.1.1.7) and the new South African variant B.1.351. Table S1: Homology of different proteins of the SARS-CoV2 with OC43, HKU1, and NL63 corona viruses, Table S2: Highly conserved candidate CD8+ T cell epitopes that had a high degree of homology (>75%) with HCoVs and a binding score of ≥0.90, Table S3: Highly conserved candidate CD8+ T cell epitopes that were specific to SARS-CoV2 (<25% homology with HCoVs) and a binding score of ≥0.90 with the SARS-CoV2 variants in different countries, Table S4: The candidate CD8+ T cell epitopes (<25% homology with other HCoVs) and their predicted HLA allele, the published CD8+ T cell epitopes (marked in red) and their HLA restriction, Table S5: The candidate CD8+ T cell epitopes (>75% homology with other HCoVs) and their predicted HLA allele, the published CD8+ T cell epitopes (marked in red) and their HLA restriction.

Author Contributions

Conceptualization, P.D.P., G.N.M. and G.S.O.; methodology, P.D.P., G.N.M. and G.S.O.; formal analysis, P.D.P. and G.N.M.; data analysis, D.M. and S.D.; funding, C.J., G.N.M. and G.S.O.; writing, P.D.P. and G.N.M.; review and editing, G.N.M., C.J. and G.S.O. All authors have read and agreed to the published version of the manuscript.

Funding

We are grateful to the Centre for Dengue Research, UK Medical Research Council and the Foreign and Commonwealth Office for support.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data is available in the manuscript and its supporting files.

Conflicts of Interest

The authors declare that they have no competing interest.

References

  1. Worldometer COVID-19 Coronavirus Outbreak. Available online: https://www.worldometers.info/coronavirus/ (accessed on 15 January 2021).
  2. Wang, G.; Wu, C.; Zhang, Q.; Yu, B.; Lu, J.; Zhang, S.; Wu, G.; Wu, Y.; Zhong, Y. Clinical characteristics and the risk factors for severe events of elderly coronavirus disease 2019 patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2020, 45, 542–548. [Google Scholar] [PubMed]
  3. Albitar, O.; Ballouze, R.; Ooi, J.P.; Sheikh Ghadzi, S.M. Risk factors for mortality among COVID-19 patients. Diabetes Res. Clin. Pract. 2020, 166, 108293. [Google Scholar] [CrossRef]
  4. Tian, W.; Jiang, W.; Yao, J.; Nicholson, C.J.; Li, R.H.; Sigurslid, H.H.; Wooster, L.; Rotter, J.I.; Guo, X.; Malhotra, R. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J. Med. Virol. 2020, 92, 1875–1883. [Google Scholar] [CrossRef]
  5. Centre, C.R. Mortality Analysis. Available online: https://coronavirus.jhu.edu/data/mortality (accessed on 23 December 2020).
  6. WHO. COVID-19 Weekly Situation Report; SEARO WHO: WHO SEARO Situation Reports, 14th May 2021; WHO South-East Asia Regional Office: New Delhi, India, 2021; p. 10. [Google Scholar]
  7. Sorci, G.; Faivre, B.; Morand, S. Explaining among-country variation in COVID-19 case fatality rate. Sci. Rep. 2020, 10, 18909. [Google Scholar] [CrossRef] [PubMed]
  8. Escobar, L.E.; Molina-Cruz, A.; Barillas-Mury, C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc. Natl. Acad. Sci. USA 2020, 117, 17720–17726. [Google Scholar] [CrossRef]
  9. Ng, K.W.; Faulkner, N.; Cornish, G.H.; Rosa, A.; Harvey, R.; Hussain, S.; Ulferts, R.; Earl, C.; Wrobel, A.G.; Benton, D.J.; et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 2020, 370, 1339–1343. [Google Scholar] [CrossRef]
  10. Lin, A.; He, Z.B.; Zhang, S.; Zhang, J.G.; Zhang, X.; Yan, W.H. Early Risk Factors for the Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Positivity in Patients with Coronavirus Disease 2019. Clin. Infect. Dis. 2020, 71, 2061–2065. [Google Scholar] [CrossRef]
  11. Peng, Y.; Mentzer, A.J.; Liu, G.; Yao, X.; Yin, Z.; Dong, D.; Dejnirattisai, W.; Rostron, T.; Supasa, P.; Liu, C.; et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 2020, 21, 1336–1345. [Google Scholar] [CrossRef] [PubMed]
  12. Grifoni, A.; Weiskopf, D.; Ramirez, S.I.; Mateus, J.; Dan, J.M.; Moderbacher, C.R.; Rawlings, S.A.; Sutherland, A.; Premkumar, L.; Jadi, R.S.; et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 2020, 181, 1489–1501.e15. [Google Scholar] [CrossRef] [PubMed]
  13. Le Bert, N.; Tan, A.T.; Kunasegaran, K.; Tham, C.Y.L.; Hafezi, M.; Chia, A.; Chng, M.H.Y.; Lin, M.; Tan, N.; Linster, M.; et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 2020, 584, 457–462. [Google Scholar] [CrossRef] [PubMed]
  14. Weiskopf, D.; Schmitz, K.S.; Raadsen, M.P.; Grifoni, A.; Okba, N.M.A.; Endeman, H.; van den Akker, J.P.C.; Molenkamp, R.; Koopmans, M.P.G.; van Gorp, E.C.M.; et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 2020, 5, 48. [Google Scholar] [CrossRef] [PubMed]
  15. Kim, Y.; Ponomarenko, J.; Zhu, Z.; Tamang, D.; Wang, P.; Greenbaum, J.; Lundegaard, C.; Sette, A.; Lund, O.; Bourne, P.E.; et al. Immune epitope database analysis resource. Nucleic Acids Res. 2012, 40, W525–W530. [Google Scholar] [CrossRef] [Green Version]
  16. Reynisson, B.; Alvarez, B.; Paul, S.; Peters, B.; Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020, 48, W449–W454. [Google Scholar] [CrossRef] [PubMed]
  17. Malavige, G.N.; Rostron, T.; Seneviratne, S.L.; Fernando, S.; Sivayogan, S.; Wijewickrama, A.; Ogg, G.S. HLA analysis of Sri Lankan Sinhalese predicts North Indian origin. Int. J. Immunogenet. 2007, 34, 313–315. [Google Scholar] [CrossRef]
  18. Shomuradova, A.S.; Vagida, M.S.; Sheetikov, S.A.; Zornikova, K.V.; Kiryukhin, D.; Titov, A.; Peshkova, I.O.; Khmelevskaya, A.; Dianov, D.V.; Malasheva, M.; et al. SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors. Immunity 2020, 53, 1245–1257.e5. [Google Scholar] [CrossRef] [PubMed]
  19. Nelde, A.; Bilich, T.; Heitmann, J.S.; Maringer, Y.; Salih, H.R.; Roerden, M.; Lubke, M.; Bauer, J.; Rieth, J.; Wacker, M.; et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 2021, 22, 74–85. [Google Scholar] [CrossRef]
  20. Ferretti, A.P.; Kula, T.; Wang, Y.; Nguyen, D.M.V.; Weinheimer, A.; Dunlap, G.S.; Xu, Q.; Nabilsi, N.; Perullo, C.R.; Cristofaro, A.W.; et al. Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity 2020, 53, 1095–1107.e3. [Google Scholar] [CrossRef]
  21. Schulien, I.; Kemming, J.; Oberhardt, V.; Wild, K.; Seidel, L.M.; Killmer, S.; Sagar; Daul, F.; Salvat Lago, M.; Decker, A.; et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. Nat. Med. 2020. [Google Scholar] [CrossRef]
  22. Grifoni, A.; Weiskopf, D.; Lindestam Arlehamn, C.S.; Angelo, M.; Leary, S.; Sidney, J.; Frazier, A.; Phillips, E.; Mallal, S.; Mack, S.J.; et al. Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 714 adults from Colombo, Sri Lanka. Hum. Immunol. 2018, 79, 87–88. [Google Scholar] [CrossRef]
  23. Ayo, C.M.; da Silveira Camargo, A.V.; Xavier, D.H.; Batista, M.F.; Carneiro, O.A.; Brandao de Mattos, C.C.; Ricci, O., Jr.; de Mattos, L.C. Frequencies of allele groups HLA-A, HLA-B and HLA-DRB1 in a population from the northwestern region of Sao Paulo State, Brazil. Int. J. Immunogenet. 2015, 42, 19–25. [Google Scholar] [CrossRef]
  24. Neville, M.J.; Lee, W.; Humburg, P.; Wong, D.; Barnardo, M.; Karpe, F.; Knight, J.C. High resolution HLA haplotyping by imputation for a British population bioresource. Hum. Immunol. 2017, 78, 242–251. [Google Scholar] [CrossRef] [PubMed]
  25. Requena, D.; Medico, A.; Chacon, R.D.; Ramirez, M.; Marin-Sanchez, O. Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country. Front. Immunol. 2020, 11, 2008. [Google Scholar] [CrossRef] [PubMed]
  26. Tomita, Y.; Ikeda, T.; Sato, R.; Sakagami, T. Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis. Immun. Inflamm. Dis. 2020, 8, 684–694. [Google Scholar] [CrossRef] [PubMed]
  27. Habel, J.R.; Nguyen, T.H.O.; van de Sandt, C.E.; Juno, J.A.; Chaurasia, P.; Wragg, K.; Koutsakos, M.; Hensen, L.; Jia, X.; Chua, B.; et al. Suboptimal SARS-CoV-2-specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype. Proc. Natl. Acad. Sci. USA 2020, 117, 24384–24391. [Google Scholar] [CrossRef] [PubMed]
  28. Peng, Y.; Mentzer, A.J.; Liu, G.; Yao, X.; Yin, Z.; Dong, D.; Dejnirattisai, W.; Rostron, T.; Supasa, P.; Liu, C.; et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients. bioRxiv 2020. [Google Scholar] [CrossRef]
  29. Mongkolsapaya, J.; Dejnirattisai, W.; Xu, X.N.; Vasanawathana, S.; Tangthawornchaikul, N.; Chairunsri, A.; Sawasdivorn, S.; Duangchinda, T.; Dong, T.; Rowland-Jones, S.; et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 2003, 9, 921–927. [Google Scholar] [CrossRef]
  30. Mongkolsapaya, J.; Duangchinda, T.; Dejnirattisai, W.; Vasanawathana, S.; Avirutnan, P.; Jairungsri, A.; Khemnu, N.; Tangthawornchaikul, N.; Chotiyarnwong, P.; Sae-Jang, K.; et al. T cell responses in dengue hemorrhagic fever: Are cross-reactive T cells suboptimal? J. Immunol. 2006, 176, 3821–3829. [Google Scholar] [CrossRef]
Table
Table 1. Predicted CD8+ epitopes of the SARS-CoV2 virus restricted through HLA-A alleles.
Table 1. Predicted CD8+ epitopes of the SARS-CoV2 virus restricted through HLA-A alleles.
9mer Peptides with a Peptide Binding Score of ≥0.90
ProteinHLA-A AlleleSequenceScoreOC43 % Identity with SARS-CoV2HKU1 % Identity with SARS-CoV2NL63 % Identity with SARS-CoV2
SpikeA*02:01269YLQPRTFLL2770.97444422
SpikeA*24:021208QYIKWPWYI12160.95777777
SpikeA*02:01976VLNDILSRL9840.94676733
SpikeA*24:02635VYSTGSNVF6430.93222222
SpikeA*02:01109TLDSKTQSL1170.91222233
MembraneA*24:0295YFIASFRLF1030.91777777
NucleocapsidA*02:01222LLLDRLNQL2300.96333333
NSP2A*02:01265GLNDNLLEI2730.92443344
NSP2A*24:02497TFFKLVNKF5050.90332222
NSP3A*24:02726YYTSNPTTF7340.99222222
NSP3A*24:021349NYMPYFFTL13570.98332211
NSP3A*24:02816YYHTTDPSF8240.9611110
NSP3A*24:02364LYDKLVSSF3720.95333311
NSP3A*24:021081YYKKDNSYF10890.9433330
NSP4A*02:01420FLLNKEMYL4280.98333333
NSP4A*02:01359FLAHIQWMV3670.94444433
NSP4A*24:02351FYLTNDVSF3590.92222222
NSP4A*24:02486LYQPPQTSI4940.90666666
NSP5A*02:06194LIQDYIQSV2020.95443311
NSP6A*02:0170FLLPSLATV780.99333344
NSP6A*02:01141TLMNVLTLV1490.92000
NSP6A*24:0284VYMPASWVM920.910011
NSP6A*24:02115MYASAVVLL1230.90222222
NSP7A*02:0112VLLSVLQQL200.95666644
NSP8A*02:01152ALWEIQQVV1600.98443322
NSP12A*24:0237IYNDKVAGF450.95664444
NSP12A*02:01123TMADLVYAL1310.93777777
NSP12A*02:06334FVDGVPFVV3420.9310010088
NSP12A*02:01854LMIERFVSL8620.91888855
NSP13 A*02:01 239 TLVPQEHYV247 0.95 777744
NSP13 A*24:02 397 VYIGDPAQL405 0.91 10010077
NSP14A*02:01321LLADKFPVL3290.94111133
NSP14A*02:01176NLSDRVVFV1840.93666677
NSP14A*02:01184VLWAHGFEL1920.92664466
NSP14A*02:01494YLDAYNMMI5020.91444444
NSP15A*02:06243SQLGGLHLL2510.96666666
NSP15A*02:01297LLLDDFVEI3050.95668888
NSP15A*02:06312SVVSKVVKV3200.94666655
NSP15A*02:06181KVDGVVQQL1890.92222211
10mer Peptides with a Peptide Biding Score of ≥0.90
ProteinHLA-A AlleleSequenceSoreOC43 % Identity with SARS-CoV2HKU1 % Identity with SARS-CoV2NL63 % Identity with SARS-CoV2
SpikeA*24:021066TYVPAQEKNF10750.94303010
SpikeA*24:02159VYSSANNCTF1680.90103020
NSP3A*24:02717VYYTSNPTTF7260.98304020
NSP6A*24:02242YDYLVSTQEF251 0.91 505050
Table
Table 2. Predicted CD8+ epitopes of the SARS-CoV2 virus restricted through HLA-B alleles.
Table 2. Predicted CD8+ epitopes of the SARS-CoV2 virus restricted through HLA-B alleles.
9mer Peptides with a Peptide Binding Score of ≥0.90
ProteinHLA-B AlleleSequenceScoreOC43 % Identity with SARS-CoV2HKU1 % Identity with SARS-CoV2NL63 % Identity with SARS-CoV2
SpikeB*35:01895IPFAMQMAY9030.99334433
SpikeB*35:0183LPFNDGVYF910.98223311
SpikeB*44:031200QELGKYEQY12080.98444433
SpikeB*35:01686VASQSIIAY6940.98000
SpikeB*40:011015AEIRASANL10230.98222244
NucleocapsidB*35:01325TPSGTWLTY3330.99222222
NucleocapsidB*44:03322MEVTPSGTW3300.9611110
NucleocapsidB*35:0179SPDDQIGYY870.92222255
NSP1B*40:0256VEKGVLPQL640.98222211
NSP1B*35:01110HVGEIPVAY1180.95221111
NSP2B*40:01195SEVGPEHSL2030.9911110
NSP2B*40:01562GETLPTEVL5700.99000
NSP2B*44:0252REHEHEIAW600.98222222
NSP3B*44:03120EEFEPSTQY1280.9911110
NSP3B*44:03546QEILGTVSW5540.9922220
NSP3B*40:011799AELAKNVSL18070.98000
NSP4B*40:02309GEYSHVVAF3170.98444433
NSP4B*35:01373VPFWITIAY3810.98334400
NSP4B*35:01174NVLEGSVAY1820.97111144
NSP5B*35:0193TANPKTPKY1010.95666644
NSP6 B*35:01 72LPSLATVAY80 0.99 444433
NSP7B*35:0141LAKDTTEAF490.91333322
NSP8B*44:034SEFSSLPSY120.99444466
NSP8B*40:0147SEFDRDAAM550.93444444
NSP9B*44:0367TELEPPCRF750.95666666
NSP10B*35:0119FAVDAAKAY270.98555555
NSP12B*44:02608VENPHLMGW6160.99777788
NSP12B*40:01874QEYADVFHL8820.98444444
NSP12B*35:01337VPFVVSTGY3450.97888855
NSP13B*35:01291FAIGLALYY2990.96667766
NSP13B*44:03141TEETFKLSY1490.96777755
NSP13B*40:01155REVLSDREL1630.95555544
NSP13B*40:02161RELHLSWEV1690.91777766
NSP14B*35:01428TPAFDKSAF4360.96444477
NSP14B*35:0319HPTQAPTHL270.94555555
NSP15B*35:0349LPVNVAFEL570.96666688
NSP15B*44:03200QEFKPRSQM2080.92333355
NSP16B*44:02141KENDSKEGF1490.94555566
10mer Peptides with a Peptide Binding Score of ≥0.90
ProteinHLA-B AlleleSequenceSoreOC43 % Identity with SARS-CoV2HKU1 % Identity with SARS-CoV2NL63 % Identity with SARS-CoV2
SpikeB*44:0295TEKSNIIRGW1040.9510010
MembraneB*44:0311EELKKLLEQW200.94402030
NSP2B*44:03489KEIKESVQTF4980.950010
NSP3B*44:03120EEEFEPSTQY1290.9820100
NSP3B*44:031072TEIDPKLDNY10810.96403010
NSP3B*35:01502VPTDNYITTY5110.94000
NSP3B*44:0394GEFKLASHMY1030.9350500
NSP7B*40:0146TEAFEKMVSL550.91504020
NSP8B*44:033ASEFSSLPSY120.94404060
NSP10B*40:015TEVPANSTVL140.92506050
NSP12B*44:03875QEYADVFHLY8840.99505040
NSP12B*44:03166VENPDILRVY1750.95807080
NSP12B*44:03608DVENPHLMGW6170.90807080
NSP13B*40:01446AEIVDTVSAL4550.96908080
NSP14B*44:0277EEAIRHVRAW860.96706060
NSP14B*35:0142IPGIPKDMTY510.92202030
NSP15B*35:01269IPMDSTVKNY2780.96303010
NSP15B*40:0140VELFENKTTL490.95503060
Table
Table 3. Predicted CD8+ epitopes of the SARS-CoV2 virus restricted through HLA-C alleles.
Table 3. Predicted CD8+ epitopes of the SARS-CoV2 virus restricted through HLA-C alleles.
9mer Peptides with a Peptide Binding Score of ≥0.90
ProteinHLA-B AlleleSequenceScoreOC43 % Identity with SARS-CoV2HKU1 % Identity with SARS-CoV2NL63 % Identity with SARS-CoV2
SpikeHLA-C*04:011137VYDPLQPEL11450.99222211
SpikeHLA-C*06:02327VRFPNITNL3350.9811110
SpikeHLA-C*03:02687VASQSIIAY6950.9711110
SpikeHLA-C*03:021054QSAPHGVVF10620.93555555
Membrane HLA-C*03:02 37 FAYANRNRF45 0.96 444422
Membrane HLA-C*03:02 170 VATSRTLSY178 0.96 333344
NSP1 HLA-C*03:02 77 RTAPHGHVM85 0.90 111111
NSP3HLA-C*03:021776YVNTFSSTF17840.96666633
NSP3HLA-C*04:01734TFDNLKTLL7420.96111111
NSP3HLA-C*03:021651VARDLSLQF16590.95443333
NSP3HLA-C*04:011772MFDAYVNTF17800.95777733
NSP3HLA-C*04:01364LYDKLVSSF3720.94333311
NSP3HLA-C*03:021735SAKSASVYY17430.90333322
NSP5 HLA-C*03:02 93 TANPKTPKY101 0.96 666644
NSP7 HLA-C*03:02 41 LAKDTTEAF490.92333322
NSP8 HLA-C*03:02 130 VVIPDYNTY1380.92445544
NSP10 HLA-C*03:02 19 FAVDAAKAY27 0.99 555555
NSP13 HLA-C*03:02 209 VVYRGTTTY217 0.95 777744
NSP13 HLA-C*03:02 291 FAIGLALYY299 0.94 777755
NSP13 HLA-C*03:02 225 FVLTSHTVM233 0.90 777777
NSP14 HLA-C*06:02 162 VRIKIVQML170 0.93 777777
Table
Table 4. Predicted CD8+ epitopes of the SARS-CoV2 virus, which show ≥75% homology with OC43, HKU1, and NL63.
Table 4. Predicted CD8+ epitopes of the SARS-CoV2 virus, which show ≥75% homology with OC43, HKU1, and NL63.
9mer Peptides with ≥75% Homology with OC43, HKU1, and NL63
ProteinHLA AlleleSequenceScoreOC43 % Identity with SARS-CoV2HKU1 % Identity with SARS-CoV2NL63 % Identity with SARS-CoV2
SpikeA*24:021208QYIKWPWYI12160.95777777
MembraneA*24:0295YFIASFRLF1030.91777777
NSP3C*04:011772MFDAYVNTF17800.95777733
NSP5A*02:06159FVYMHQLEL1670.761008866
NSP5B*35:0195NPKTPKYKF1030.47777755
NSP10B*35:0336QPITNCVKM440.74888866
NSP12A*02:01123TMADLVYAL1310.93777777
NSP12A*02:06334FVDGVPFVV3420.9310010088
NSP12A*02:01854LMIERFVSL8620.91888855
NSP12A*02:01334FVDGVPFVV3420.9010010077
NSP12B*44:03608VENPHLMGW6160.99777788
NSP12B*35:01337VPFVVSTGY3450.97888855
NSP12C*03:02534NVIPTITQM5420.82777766
NSP12C*03:02340FVVSTGYHF3480.80777755
NSP13 A*02:01 239 TLVPQEHYV247 0.95 777744
NSP13 A*24:02 397 VYIGDPAQL405 0.91 10010077
NSP13 A*02:06 239 TLVPQEHYV247 0.91 777744
NSP13B*35:01291FAIGLALYY2990.96777766
NSP13B*44:03141TEETFKLSY1490.96777755
NSP13B*40:02161RELHLSWEV1690.91777766
NSP13 C*03:02 209 VVYRGTTTY217 0.95 777744
NSP13 C*03:02 291 FAIGLALYY299 0.94 777755
NSP13 C*03:02 225 FVLTSHTVM233 0.90 777777
NSP13 C*06:02 211 YRGTTTYKL219 0.78 888855
NSP14A*02:01176NLSDRVVFV1840.93776677
NSP14B*35:01509WVYKQFDTY5170.65777755
NSP14 C*06:02 162 VRIKIVQML170 0.93 777777
NSP14 C*03:02 487 HANEYRLYL495 0.83 777755
NSP15A*02:01297LLLDDFVEI3050.95668888
NSP15B*35:0349LPVNVAFEL570.96776688
NSP16A*02:0153YLNTLTLAV610.89888855
NSP16A*24:0246KYTQLCQYL540.82100100100
NSP16A*33:03247MSKFPLKLR2550.78777744
NSP16 C*04:01 131 MYDPKTKNV139 0.83 777744
10mer Peptides with ≥75% Homology with OC43, HKU1, and NL63
ProteinHLA AlleleSequenceSoreOC43 % Identity with SARS-CoV2HKU1 % Identity with SARS-CoV2NL63 % Identity with SARS-CoV2
NSP4C*03:02478FSNSGSDVLY4870.41807020
NSP12A*02:06332KIFVDGVPFV3410.88909070
NSP12A*02:01332KIFVDGVPFV3410.88909070
NSP13A*24:02216TYKLNVGDYF2250.77807050
NSP13A*02:0140KLVLSVNPYV490.58808050
NSP13A*33:03381NYDLSVVNAR3900.54808080
NSP13A*33:03551ETAHSCNVNR5600.52909080
NSP13B*40:01446AEIVDTVSAL4550.96908080
NSP13B*40:02446AEIVDTVSAL4550.87908080
NSP14A*33:03516TYNLWNTFTR5250.58808050
NSP14A*24:02510VYKQFDTYNL5190.55808060
NSP15A*33:0352NVAFELWAKR610.66806090
NSP15A*02:06243SQLGGLHLLI2520.52707080
NSP16A*24:02241SYSLFDMSKF2500.75808050
NSP16A*33:03246DMSKFPLKLR2550.59807050
NSP16A*24:02221GYVMHANYIF2300.55808070
NSP16A*02:01243SLFDMSKFPL2520.47908050
Table
Table 5. Predicted CD8+ epitopes of the SARS-CoV2 virus, which show ≤25% homology with OC43, HKU1, and NL63.
Table 5. Predicted CD8+ epitopes of the SARS-CoV2 virus, which show ≤25% homology with OC43, HKU1, and NL63.
9mer Peptides with ≤25% Homology with OC43, HKU1, and NL63
ProteinHLA AlleleSequenceScoreOC43 % Identity with SARS-CoV2HKU1 % Identity with SARS-CoV2NL63 % Identity with SARS-CoV2
SpikeA*24:02635VYSTGSNVF6430.93222222
SpikeA*02:01109TLDSKTQSL1170.91222233
SpikeB*35:0183LPFNDGVYF910.98223311
SpikeB*35:01686VASQSIIAY6940.98000
SpikeB*40:011015AEIRASANL10230.98222244
SpikeC*04:011137VYDPLQPEL11450.99222211
SpikeC*06:02327VRFPNITNL3350.9811110
SpikeC*03:02687VASQSIIAY6950.9711110
SpikeC*07:01327VRFPNITNL3350.8711110
SpikeC*07:02327VRFPNITNL3350.8411110
SpikeC*06:02402IRGDEVRQI4100.8311110
SpikeC*04:0178RFDNPVLPF860.83111111
MembraneA*33:03138LVIGAVILR1460.72222222
Membrane B*40:01 136 SELVIGAVI 1440.73111111
EnvelopeA*33:0361RVKNLNSSR690.6111110
EnvelopeA*33:0330TLAILTALR380.60222211
EnvelopeB*40:016SEETGTLIV140.55112211
EnvelopeB*35:034FVSEETGTL120.43111111
NucleocapsidB*35:01325TPSGTWLTY3330.99222222
NucleocapsidB*44:03322MEVTPSGTW3300.9611110
Nucleocapsid C*03:03 403 FSKQLQQSM411 0.73 111111
NSP1A*24:02135SYGADLKSF1430.89000
NSP1A*02:0184VMVELVAEL920.8522220
NSP1B*40:0256VEKGVLPQL640.98222211
NSP1B*35:01110HVGEIPVAY1180.95221111
NSP1B*35:0189VAELEGIQY970.6311011
NSP1 C*03:02 77 RTAPHGHVM85 0.90 111111
NSP1 C*03:02 110 HVGEIPVAY118 0.81 221111
NSP1 C*03:02 165 HSSGVTREL173 0.71 11110
NSP2A*24:02497TFFKLVNKF5050.90332222
NSP2A*02:06420YITGGVVQL4280.86222222
NSP2A*02:06439TVYEKLKPV4470.83111111
NSP2B*40:01195SEVGPEHSL2030.9911110
NSP2B*40:01562GETLPTEVL5700.99000
NSP2B*44:0352REHEHEIAW600.98222222
NSP2 C*06:02 363 VRSIFSRTL371 0.88 111111
NSP2 C*03:02 387 TILDGISQY395 0.73 222222
NSP3A*24:02726YYTSNPTTF7340.99222222
NSP3A*24:021349NYMPYFFTL13570.98332211
NSP3A*24:02816YYHTTDPSF8240.9611110
NSP3B*44:03120EEFEPSTQY1280.9911110
NSP3B*44:03546QEILGTVSW5540.9922220
NSP3B*40:011799AELAKNVSL18070.98000
NSP3C*04:01734TFDNLKTLL7420.96111111
NSP3C*07:02718YYTSNPTTF7260.89222222
NSP3C*03:02768MSMTYGQQF7760.87222233
NSP3C*03:02336FGADPIHSL3440.87222222
NSP3C*03:021436MSNLGMPSY14440.80111111
NSP4A*24:02351FYLTNDVSF3590.92222222
NSP4B*35:01174NVLEGSVAY1820.97111144
NSP4 C*03:02 25 YLITPVHVM330.87111111
NSP4 C*03:02 174 NVLEGSVAY1820.73222222
NSP6A*02:01141TLMNVLTLV1490.92000
NSP6A*24:0284VYMPASWVM920.910011
NSP6A*24:02115MYASAVVLL1230.90222222
NSP6 B*35:01 156NALDQAISM164 0.88 222211
NSP6 B*35:01 167LIISVTSNY175 0.56 111122
NSP6 C*04:01 131 VYDDGARRV139 0.89 111111
NSP14A*02:01321LLADKFPVL3290.94111133
NSP15A*02:06181KVDGVVQQL1890.92222211
10mer Peptides with ≤25% Homology with OC43, HKU1, and NL63
ProteinHLA AlleleSequenceSoreOC43 % Identity with SARS-CoV2HKU1 % Identity with SARS-CoV2NL63 % Identity with SARS-CoV2
SpikeA*24:02368LYNSASFSTF3770.89202030
SpikeA*24:02788IYKTPPIKDF7970.88102010
SpikeB*44:0295TEKSNIIRGW1040.9510010
SpikeB*35:01229LPIGINITRF2380.82102020
SpikeC*04:01932TVYDPLQPEL9410.59202010
SpikeC*07:0177KRFDNPVLPF860.47101010
MembraneA*33:03137ELVIGAVILR1460.65202020
MembraneA*33:03177SYYKLGASQR1860.55402020
MembraneB*40:01136SELVIGAVIL1450.76101020
EnvelopeA*33:0360SRVKNLNSSR690.4810300
EnvelopeA*33:0329VTLAILTALR380.4130200
NucleocapsidA*33:03140NTPKDHIGTR1490.60201020
NucleocapsidA*02:01398ADLDDFSKQL4070.4410300
NucleocapsidB*44:03321GMEVTPSGTW3300.87000
NucleocapsidB*35:01324VTPSGTWLTY3330.68202020
NucleocapsidB*40:01322MEVTPSGTWL3310.6710100
NSP1A*33:03162NTKHSSGVTR1710.74000
NSP1A*33:0368YVFIKRSDAR770.49302010
NSP1A*02:0614VQLSLPVLQV230.45201010
NSP1A*33:0315QLSLPVLQVR240.40101010
NSP1B*35:0161LPQLEQPYVF700.81202030
NSP1B*40:02112GEIPVAYRKV1210.54302020
NSP1B*40:029NEKTHVQLSL180.49202020
NSP1B*35:0361LPQLEQPYVF700.43202030
NSP1B*35:0318LPVLQVRDVL270.41202010
NSP1C*15:027RTAPHGHVMV160.52301010
NSP2A*02:01389ILDGISQYSL3980.650010
NSP2A*33:03529FVTHSKGLYR5380.610030
NSP2A*02:01288KLNEEIAIIL2970.59101030
NSP2A*24:021AYTRYVDNNF100.59302020
NSP2B*44:03489KEIKESVQTF4980.950010
NSP2B*44:03452EEKFKEGVEF4610.89101030
NSP2B*40:01344GEQKSILSPL3530.85101020
NSP2C*03:02224IAFGGCVFSY2330.59101020
NSP3A*24:0216QGYKSVNITF250.79102020
NSP3A*24:021040EYKGPITDVF10490.7520200
NSP3B*44:03120EEEFEPSTQY1290.9820100
NSP3B*35:01502VPTDNYITTY5110.94000
NSP4A*02:06101FVVPGLPGTI1100.65201050
NSP4B*40:0197REVGFVVPGL1060.73201050
NSP5A*24:02125VYQCAMRPNF1340.50202040
NSP6A*33:0384VYMPASWVMR93 0.53 0010
NSP6B*35:0143LPFAMGIIAM52 0.71 0010
NSP7B*44:0373EEMLDNRATL820.58101040
NSP8A*02:01151SALWEIQQVV1600.68203020
NSP8C*03:0213AAFATAQEAY220.45101040
NSP14B*35:0142IPGIPKDMTY510.92202030
NSP15A*33:03215ELAMDEFIER2240.57402020
NSP15B*44:03169GEAVKTQFNY1780.74101010
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Pushpakumara, P.D.; Madhusanka, D.; Dhanasekara, S.; Jeewandara, C.; Ogg, G.S.; Malavige, G.N. Identification of Novel Candidate CD8+ T Cell Epitopes of the SARS-CoV2 with Homology to Other Seasonal Coronaviruses. Viruses 2021, 13, 972. https://doi.org/10.3390/v13060972

AMA Style

Pushpakumara PD, Madhusanka D, Dhanasekara S, Jeewandara C, Ogg GS, Malavige GN. Identification of Novel Candidate CD8+ T Cell Epitopes of the SARS-CoV2 with Homology to Other Seasonal Coronaviruses. Viruses. 2021; 13(6):972. https://doi.org/10.3390/v13060972

Chicago/Turabian Style

Pushpakumara, Pradeep Darshana, Deshan Madhusanka, Saubhagya Dhanasekara, Chandima Jeewandara, Graham S. Ogg, and Gathsaurie Neelika Malavige. 2021. "Identification of Novel Candidate CD8+ T Cell Epitopes of the SARS-CoV2 with Homology to Other Seasonal Coronaviruses" Viruses 13, no. 6: 972. https://doi.org/10.3390/v13060972

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop